Document Detail

Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure.
MedLine Citation:
PMID:  17565925     Owner:  NLM     Status:  MEDLINE    
It is well known that epoetin alfa increases serum endothelin (ET)-1 and blood pressure. No data are available, however, on the effects of darbepoetin alfa on serum ET-1 and blood pressure. This study was conducted to compare the effects of darbepoetin alfa and epoetin alfa on serum ET-1 and blood pressure in patients on hemodialysis (HD). A total of 42 patients on HD were included in the study. Serum samples for measuring levels of ET-1 were taken 30 min after administration of epoetin alfa. After blood samples had been taken from all patients, epoetin alfa was changed to darbepoetin alfa. Three months after the start of darbepoetin alfa treatment, blood samples were taken to measure the same parameters. Mean arterial blood pressure was measured before recombinant human erythropoietin (EPO) administration and 30 min after EPO administration while patients were taking epoetin alfa or darbepoetin alfa. Injection of epoetin alfa or darbepoetin alfa significantly increased serum ET-1 levels compared with levels in those patients who were not on EPO therapy (P<.05). When the effects of epoetin alfa on serum ET-1 level were compared with those of darbepoetin alfa, the 2 types of EPO were found to increase serum ET-1 levels similarly (P>.05). Administration of epoetin alfa or darbepoetin alfa increased systolic and diastolic blood pressures significantly over values in the control group (P<.05). Serum systolic and diastolic blood pressures increased similarly after injection of epoetin alfa or darbepoetin alfa. Administration of darbepoetin alfa increased blood pressure in patients on HD in a way that was positively correlated with enhanced ET-1 release; a similar correlation was noted with epoetin alfa.
Mehmet Kanbay; Ali Akcay; Tuncay Delibasi; Burak Uz; Arif Kaya; Cemile Koca; Faruk Turgut; Nuket Bavbek; Ebru Uz; Murat Duranay; Ramazan Yigitoglu
Related Documents :
7518545 - Cardiovascular effects of human parathyroid hormone and parathyroid hormone-related pep...
8360735 - Evaluation of pressure changes in feeding arteries during embolization of intracerebral...
6848155 - Cimetidine and portal pressure in chronic liver disease.
1484155 - Blockade of atp-sensitive k+ channels by glibenclamide reduces portal pressure and hype...
2908305 - Dose-effect relationship of carvedilol in essential hypertension. an open study.
19019665 - Gastroesophageal regurgitation during anesthesia and controlled ventilation with six ai...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2007-06-13     Completed Date:  2007-07-31     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  346-52     Citation Subset:  T    
Department of Nephrology, Fatih University School of Medicine, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*
Endothelin-1 / blood*
Erythropoietin / adverse effects*,  analogs & derivatives*
Hematinics / adverse effects*
Recombinant Proteins
Renal Dialysis
Reg. No./Substance:
0/Endothelin-1; 0/Hematinics; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 113427-24-0/epoetin alfa; 15UQ94PT4P/darbepoetin alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis.
Next Document:  Pertussis in adolescents.